At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BCTX BriaCell Therapeutics Corp.
Post-Market Trading 11-26 17:19:31 EST
0.7471
+0.0661
+9.71%
盘后0.7399
-0.0072-0.96%
16:40 EST
High0.7490
Low0.6614
Vol2.54M
Open0.7150
D1 Closing0.6810
Amplitude12.86%
Mkt Cap26.77M
Tradable Cap23.39M
Total Shares35.84M
T/O1.85M
T/O Rate8.12%
Tradable Shares31.31M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
BriaCell Highlights Promising Breast Cancer Trial Results
BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.